Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Supernus Acquires US WorldMeds’ CNS Portfolio | Contract Pharma

What are you searching for?

Sign in
Breaking News

Supernus Acquires US WorldMeds’ CNS Portfolio

Adds three marketed products in the U.S. and a product candidate in late-stage development.

By: Contract Pharma

Contract Pharma Staff

Supernus Pharmaceuticals, Inc. has entered into a definitive agreement to acquire US WorldMeds’ CNS portfolio, adding three marketed products in the U.S. and a product candidate in late-stage development.

Products include APOKYN (apomorphine hydrochloride) injection for Parkinson’s disease (PD); MYOBLOC (rimabotulinumtoxinB) injection for the treatment of pain associated with cervical dystonia; XADAGO (safinamide) tablets indicated as an adjunctive treatment for PD episodes; and Apomorphine Infusion Pump, a product candidate for the continuous treatment of motor fluctuations in PD patients. New Drug Application (NDA) submission is expected in 2H20 with potential launch, if approved by the FDA, in 2H21.

“This acquisition aligns extremely well with our strategy of expanding and enhancing our commercial and late-stage assets and is a significant step in strengthening our leadership position in CNS,” said Jack Khattar, President and CEO of Supernus. “We expect this transaction to provide Supernus with enhanced operating cash flow, financial flexibility to execute on our strategy, and a continued strong balance sheet. In addition, the transaction provides increased revenue scale and adds new commercial capabilities that are important for orphan drugs and specialty pharmacy products.”

“The core values of Supernus align very well with US WorldMeds.  We expect a seamless transition with even more patients benefiting from these products under Supernus’ stewardship.  This transaction will allow US WorldMeds to focus on growing our other exciting business units,” commented Paul Breckinridge “Breck” Jones, Sr., Chief Executive Officer of US WorldMeds.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics